Selective depletion of C-reactive protein by therapeutic apheresis (CRP-apheresis) in acute myocardial infarctio

Not Applicable

• Conditions: I21; Acute myocardial infarction

• Registration Number: DRKS00008988
• Lead Sponsor: Pentracor GmbH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2015-08-06
• Study Completion: 2019-11-22
• Results First Posted: 2021-03-10
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 83

Inclusion Criteria

• STEMI as defined by the guidelines of the European Society of Cardiology (ESC) for the treatment of AMI in patients with ST-segment elevation.
• TIMI III flow after PCI (stent implantation)
• Killip-Class = II
• 2 - 12 h from onset of symptoms until coronary reperfusion
• Informed consent
• Legal competence

Exclusion Criteria

• Previous myocardial infarction
• Acute infectious disease (body temperature (auricular, sublingual) > 38.0 °C)
• Systolic blood pressure < 100 mmHg
• Known hypersensitivity to therapeutic apheresis
• Cardiogenic shock
• Dialysis dependent renal insufficiency
• Previous coronary artery bypass surgery
• Contraindication for MRI (e.g. non-MRI-capable implants, claustrophobia)
• Malignant or chronic inflammatory disease
• Pregnancy or lactation period
• Limited possibility to join the follow-up examination (e.g., patient lives abroad)
• Participation in other interventional trials

Study & Design

• Study Type: interventional
• Study Design: Not specified